CurveBeam AI's Days Sales Outstanding for the
six
months ended in Dec. 2025 was 120.23.
CurveBeam AI's Days Inventory for the
six
months ended in Dec. 2025 was 591.37.
CurveBeam AI's Days Payable for the
six
months ended in Dec. 2025 was 112.31.
Therefore, CurveBeam AI's Cash Conversion Cycle (CCC) for the
six
months ended in Dec. 2025 was 599.29.
CurveBeam AI (ASX:CVB) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
CurveBeam AI Cash Conversion Cycle Related Terms
CurveBeam AI Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CVB vs ABT, SYK, MDT: Cash Conversion Cycle Comparison
For the Medical Devices subindustry, CurveBeam AI's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI Cash Conversion Cycle vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
CurveBeam AI's Cash Conversion Cycle for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CurveBeam AI (ASX:CVB) has a Cash Conversion Cycle of 599.29 as of Dec. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CurveBeam AI and its competitors.
Is CurveBeam AI's Cash Conversion Cycle too high?
CurveBeam AI's current Cash Conversion Cycle is 599.29. The Medical Devices & Instruments industry median Cash Conversion Cycle is 156.96. CurveBeam AI's value of 599.29 is 281.8% above this industry median.
How does CurveBeam AI's Cash Conversion Cycle compare to ABT and SYK?
CurveBeam AI's Cash Conversion Cycle of 599.29 can be compared against companies in the Medical Devices & Instruments industry. The industry median Cash Conversion Cycle is 156.96. CurveBeam AI's value of 599.29 is 281.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Devices & Instruments company?
The median Cash Conversion Cycle among Medical Devices & Instruments companies is 156.96, based on 819 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CurveBeam AI's current Cash Conversion Cycle of 599.29 is 281.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median Cash Conversion Cycle is 156.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current Cash Conversion Cycle is 599.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Cash Conversion Cycle of 599.29. The current Cash Conversion Cycle is 599.29 and 281.8% above the Medical Devices & Instruments industry median of 156.96. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Cash Conversion Cycle is 599.29 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 